Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Letrozole 25 Fulvestrant 25 Specimen Handling 19 ribociclib 16 Capecitabine 16 pembrolizumab 14 palbociclib 14 Paclitaxel 14 Trastuzumab 13 Carboplatin 13 exemestane 12 abemaciclib 12 Tamoxifen 12 Anastrozole 12 Magnetic Resonance Spectroscopy 11 trastuzumab deruxtecan 8 pertuzumab 8 Biopsy 8 Goserelin 7 inavolisib 6 giredestrant 6 Cyclophosphamide 6 130-nm albumin-bound paclitaxel 6 patritumab deruxtecan 5 eribulin 5 elacestrant 5 Taxes 5 Standard of Care 5 Radiotherapy 5 Gonadotropin-Releasing Hormone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × tucatinib × 30 days × Clear all

NCT06686394 2026-05-22

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡